Latest Non Dilutive Funding News

Western Gold Resources has completed over 45% of its 35,300-metre grade control and infill drilling program at the Gold Duke Project, receiving initial assay results from the Eagle prospect. The company is finalizing an updated scoping study and secured $3 million in non-dilutive funding to support a planned mining start in late 2025.

Neurizon Therapeutics has locked in a significant R&D tax incentive advance covering overseas and domestic development costs for its lead ALS drug candidate NUZ-001, accelerating its clinical progress with a $5.6 million rebate expected in 2025.

Elevra Lithium finalizes merger of Piedmont and Sayona, creating North America’s largest hard-rock lithium producer with a combined resource base of 229Mt. The company outlines ambitious growth plans, operational efficiencies, and a strengthened financial position to capitalize on rising lithium demand.

Everest Metals has initiated a 2,500m drilling campaign at its Mt Edon project in Western Australia, aiming to upgrade and expand its significant rubidium resource amid rising global demand for this critical mineral.

Firebird Metals has secured a strategic partnership with Kazakhstan-based Taza Metal Technologies to co-fund the development of next-generation manganese-rich battery cathodes, reinforcing its position in the evolving EV materials market.

Cambium Bio has struck a licensing deal with Keke Medtech to commercialise its fibrin biologic in dental applications, unlocking new markets and non-dilutive funding.

Lumos Diagnostics, backed by BARDA, is set to begin a pivotal pediatric clinical study to extend the use of its rapid respiratory infection test, FebriDx, to children aged 2–12 in U.S. CLIA-waived settings, potentially unlocking a $1 billion market.

Hartshead Resources has struck a pivotal Well Carry Agreement with RockRose Energy, securing full funding for its Phase C drilling costs while trimming its joint venture stake. The move also triggers a licence extension application amid UK regulatory delays.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.

EMVision Medical Devices reported a sharp increase in FY25 losses alongside a 51% revenue drop, yet marked significant progress in clinical trials for its innovative brain scanners and secured $8 million in government grants to fuel commercialisation.

IRIS Metals has agreed to sell its Kookynie Gold Project to Arika Resources, securing cash and equity to fuel its lithium ambitions in the US. This strategic move realigns IRIS’s portfolio towards critical minerals while retaining exposure to Kookynie through Arika shares.